Helus Pharma corrects press release on TARA Mind partnership for Phase 3 MDD trial, reaffirming alignment with executive order on mental health. HLP003 targetsHelus Pharma corrects press release on TARA Mind partnership for Phase 3 MDD trial, reaffirming alignment with executive order on mental health. HLP003 targets

Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus

2026/05/01 21:05
Okuma süresi: 2 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen [email protected] üzerinden bizimle iletişime geçin.

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 press release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs, though the company reaffirmed the collaboration’s alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.

The partnership is designed to support Phase 3 recruitment for Helus Pharma’s HLP003 program, which targets major depressive disorder, and to expand outreach in veteran communities. HLP003 is a proprietary novel serotonergic agonist (NSA) that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is currently enrolling patients for Phase 3 clinical development of HLP003 as an adjunctive treatment for major depressive disorder.

Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to developing synthetic molecules that activate serotonin pathways to promote neuroplasticity. The company’s proprietary NSAs are intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. In addition to HLP003, Helus Pharma is developing HLP004, another proprietary NSA in Phase 2 clinical development for generalized anxiety disorder.

The correction follows the company’s earlier announcement and clarifies the scope of the partnership with TARA Mind. The original press release can be viewed at https://ibn.fm/re8HL. Helus Pharma continues to operate in Canada, the United States, the United Kingdom, and Ireland, and provides updates on its website at www.helus.com.

The company’s newsroom, available at https://ibn.fm/HELP, provides the latest updates on its programs and initiatives. Helus Pharma’s focus on serotonergic agonists aims to improve the treatment landscape for mental health conditions by offering durable improvements through neuroplasticity.

This correction highlights the importance of accurate communication in clinical-stage pharmaceutical companies, especially when partnerships involve sensitive populations such as veterans. The alignment with the executive order underscores the broader push to enhance mental health treatments and increase clinical research participation among underserved groups.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus.

The post Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus appeared first on citybuzz.

Piyasa Fırsatı
Taraxa Coin Logosu
Taraxa Coin Fiyatı(TARA)
$0.00003973
$0.00003973$0.00003973
+2.98%
USD
Taraxa Coin (TARA) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

KAIO Global Debut

KAIO Global DebutKAIO Global Debut

Enjoy 0-fee KAIO trading and tap into the RWA boom